They know what they’re talking about, and it’s ‘a large panel of opportunities’.
Health software group Dedalus has partnered with AI data solutions firm LynxCare to expand the value of medical information of Trials For Care (T4C), from trial recruitment to encompass real-world evidence studies.
T4C is a data-as-a-service gateway solution, which offers a secure research network over a number of hospitals and healthcare providers, leveraging advanced technologies to make the data accessible and searchable using advanced AI and broad natural language processing to empower clinical research and patient care.
“Through this collaboration, we are creating a synergistic combination between T4C and LynxCare’s advanced solutions, services leveraging deep data extraction with therapeutic area-specific high precision NLP for deeper and more actionable insights,” said the Dedalus company announcement.
“Together, we propose a large panel of opportunities for clinicians, hospitals and life science industries, meeting their needs for high quality data and insights throughout their value chain.”
The collaboration will allow the enrichment of datasets, toward the generation of precision and actionable insights thanks to disease-specific data extraction workflows.
“Our mission is to support healthcare professionals and the life sciences industry by improving access to consolidated hospital data and facilitating informed medical decisions,” said Dedalus’ general manager of ANZ, Travis Stephenson.
“Our solution is designed to help healthcare teams more effectively identify clinical trial candidates and analyse patient journeys, supporting clinical science and biomedical research advancements.”
Hospitals and healthcare providers using T4C, along with LynxCare’s capabilities, will have expanded resources to support both prospective and retrospective studies. The platform is designed to facilitate collaborations across institutions and with the life sciences industry.
“Our joint solution … transforms structured and unstructured electronic health record data into a high definition and up-to-date picture of the patients’ journey, enhancing the depth and precision of a broad range of investigations, said LynxCare CEO Jeanne Kehren.
“We have demonstrated the value of this approach across various therapeutic areas, including immuno-oncology, oncology and cardiovascular disease, showing how interoperable standards can enhance research collaborations.
“Our mission is to support data-driven advancements in patient treatment and foster innovation.”